This study was a prospective, uncontrolled, central registration system, multicenter, domestic observational study (special drug-use surveillance) to evaluate the safety of 52-week clinical treatment with Beovu kit for intravitreal injection in nAMD patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of patients with adverse events in the eyes on therapy
Timeframe: 52 weeks
Number of patients with adverse events in other parts of the body (non-ocular)
Timeframe: 52 weeks